To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
NCT02528760 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83
Last updated 2017-11-21
Summary
1. All patients with chronic liver disease admitted in ICU (Intensive Care Unit) to be screened.
2. Patients fulfilling criteria for feed intolerance to be included in the study.
3. Patients to undergo routine biochemical and hematological testing including CBC, KFT, LFT, PT/INR, electrolytes baseline and daily along with ABG (Arterial Blood gas) analysis.
4. Patients with ascites to be tested for presence or absence of SBP (Spontaneous Bacterial Peritonitis).
5. Cultures to be sent as based on clinical parameter of the patient.
6. All correctable causes for intra abdominal hypertension to be corrected including electrolyte imbalance, grade III ascites, intra abdominal infection.
7. Symptoms- Absent bowel sounds (BS)= no BS detected by auscultation. Vomiting/regurgitation= any visible regurgitation of gastric contents; Diarrhoea= liquid stool \> or =3 times/day; Bowel distension= suspected clinically and radiologically confirmed; Large gastric residual volume (GRV) of \>or =500 ml/24 h on a single day or \> 200ml at any time of the day.
8. Per abdomen findings to be checked daily including presence of bowel sounds, tenderness, development of abdominal distension, abdominal girth monitoring and abdominal pressure monitoring.
9. Patients who develop feed intolerance will be included.
10. Feed intolerance to be defined as per study definition (3 out of 5 symptoms).
11. Measurement of GRV (Gastric residual volume) to be done at 4 hourly interval.
12. Methods for measuring GRV by either gravity drainage by connecting a gastric tube to a drainage bag for 10min or by manual aspiration of content using a 50ml syringe.
13. Once feed intolerance develop than every 6 hourly intra abdominal pressure monitoring and abdominal girth monitoring to be done (24)
14. Intra bladder pressure to be measured using Foleys manometer technique (25).
15. Pressure measured in cm of water to be converted into mm of Hg.
16. X ray abdomen supine to look for bowel distension, defined as more than 3 cm for small bowel and more than 5 cm in large bowel.
17. Development of intra abdominal hypertension based on intra abdominal pressure.
18. Patient to be stratified according to the grade of intra-abdominal hypertension.
19. After correction of all correctable causes, if feed intolerance persists, then patient to be randomized by block randomization method into 3 arms, metaclopromide group, erythromycin group or placebo group.
20. Daily assessment of bowel sounds, abdominal pressure, abdominal girth every 6 hourly and gastric residual volume to be noted every 4 hourly.
21. Response of therapy to be assessed at 24 hours in each arm.
22. Response to be assessed by resolution of feed intolerance or initiation of entral nutrition.
23. Metoclopromide to be given 10mg iv 8 hourly.
24. Erythromycin to be given 70mg iv 12 hourly (26).
25. Placebo arm to receive normal saline in 10ml syring twice daily.
26. After 24 hours of treatment if symptoms do not resolve than rescue treatment will be given to each arm which may include continuation of prokinetics, add on prokinetic, flatus tube insertion for bowel decompression, upgradation of antibiotics or search for any other cause, as per the patient response.
27. Therapy to continue for a total duration of 72 hours.
28. If there is no response at 72 hours, than study stops.
29. If patient responds to given treatment, study to continue for a total duration of 7 days.
30. Assessment to continue in each arm for a maximum period of 7 days.
Conditions
- Cirrhosis
Interventions
- DRUG
-
Metaclopramide
23\. Metoclopromide to be given 10mg iv 8 hourly
- DRUG
-
Erythromycin
Erythromycin to be given 70mg iv 12 hourly.
- OTHER
-
Placebo
Sponsors & Collaborators
-
Institute of Liver and Biliary Sciences, India
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-24
- Primary Completion
- 2017-08-31
- Completion
- 2017-08-31
Countries
- India
Study Locations
More Related Trials
-
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial
NCT03892070 ·Status: UNKNOWN ·Phase: NA
-
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
NCT01676285 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
NCT04073290 ·Status: RECRUITING ·Phase: PHASE4
-
Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial
NCT00678613 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
HMB for Denutrition in Patients With Cirrhosis (HEPATIC)
NCT03285217 ·Status: COMPLETED ·Phase: NA
-
Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease
NCT02140294 ·Status: COMPLETED ·Phase: NA
-
Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage
NCT00553423 ·Status: UNKNOWN ·Phase: PHASE3
-
The Natural History and Prognostic Factors of Compensated Cirrhosis.
NCT03144700 ·Status: UNKNOWN
-
Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C
NCT03633279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices
NCT02583698 ·Status: COMPLETED ·Phase: NA
-
Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)
NCT00772057 ·Status: COMPLETED ·Phase: NA
-
Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis
NCT05033327 ·Status: COMPLETED ·Phase: NA
-
Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
NCT05526404 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Oral Lactulose Versus Lactulose Enema in Hepatic Encephalopathy
NCT05788627 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
NCT00740142 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Early Enteral Nutrition on Endoscopic Therapy of Esophagogastric Varices in Liver Cirrhosis
NCT04823780 ·Status: COMPLETED
-
Impact of Continuous Renal Replacement Therapy on Systemic Hemodynamics and Lactate Clearance in Critically Ill Cirrhotics With Septic Shock.
NCT04949178 ·Status: UNKNOWN
-
Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
NCT05724485 ·Status: COMPLETED ·Phase: PHASE4
-
To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics.
NCT03448770 ·Status: UNKNOWN ·Phase: NA
-
Growth Hormone in Decompensated Liver Cirrhosis
NCT05253287 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure
NCT02718079 ·Status: COMPLETED ·Phase: NA
-
Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.
NCT07108075 ·Status: RECRUITING ·Phase: NA
-
Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
NCT05700695 ·Status: COMPLETED ·Phase: PHASE1
-
To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites
NCT02649335 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury
NCT02686385 ·Status: TERMINATED ·Phase: NA